

PRESS RELEASE

Munich, May 19, 2017 (fcf) - **FCF Fox Corporate Finance initiates a EUR 20 million EIB debt financing to Biofrontera AG**

Based on the strong relationship to the European Investment Bank (EIB), FCF Fox Corporate Finance initiated a EUR 20 million debt facility to Biofrontera AG (Biofrontera), a leading biopharmaceutical company in the field of skin cancer treatments.

The publicly listed company is headquartered in Leverkusen and employs around 100 people globally. Biofrontera primarily focuses on the discovery, development, and distribution of dermatological drugs and dermatologically tested cosmetics for the treatment and care of diseased skin. Their flagship products are the prescription drug Ameluz® and the BF-RhodoLED® lamp. With Ameluz®, Biofrontera has specialized itself on the treatment of actinic keratosis (sun-induced skin cancer). To enhance the efficacy of Ameluz®, Biofrontera employs photodynamic therapy in the form of the in-house developed BF-RhodoLED® lamp.

The EIB loan facility covers up to 50% of the estimated mid-term R&D spendings, which includes R&D staffing costs and R&D expenses. The funds will enable the development of new products and secure the strategic expansion into key markets. Specifically, the facility will enable Biofrontera to further broaden the indications for Ameluz® and new products. In addition, the funds will accelerate the clinical trials for BF-derm1, used in the treatment of chronic, antihistamine-refractory urticaria and BF-1, used to counteract migraine prophylaxis.

The InnovFin initiative, backed by the European Investment Bank and European Council, is designed to promote innovative and fast-growing companies within the European Union. InnovFin builds on the success of the Risk-Sharing Finance Facility developed under the seventh EU framework program for research and technological development (FP7). Over the period 2007-2013, 114 R&I projects totaling EUR 11.3bn were financed and loan guarantees for another EUR 1.4bn provided. The InnovFin MidCap Growth Finance Program enables the EIB to lend between EUR 7.5m and EUR 50.0m via long-term senior, junior or mezzanine facilities to innovative, R&D-heavy SMEs.

ABOUT FCF FOX CORPORATE FINANCE

FCF is a specialized **Investment Bank and Financing Specialist** advising public and private mid-market companies in the German speaking regions. FCF was founded in 2005 by investment banker Arno Fuchs. The company serves mid-market clients with an annual turnover of 10 million to 1 billion Euros from traditional German industries such as engineering, pharma, automotive, aerospace and defense, consumer products, ICT, retail and fashion. FCF arranges, structures, and places equity and debt capital and supports its clients' growth, IPO/Pre-IPO, acquisition and standard balance sheet (re-)financing strategies. FCF is a team of highly motivated and entrepreneurial minded financing specialists, enabling their clients to implement capital structures with leading German and international investors and lenders at the best available terms.

Media Contact

FCF Fox Corporate Finance GmbH
T: +49-89-20 60 4090
F: +49-89-20 60 409 -299

Maximilianstrasse 12-14
80539 München
www.fcf.de